PDCD1 and non-small cell lung carcinoma: The development of immunotherapies, particularly antibodies that inhibit the PD-1/PD-L1 pathways, has revolutionized the treatment of patients worldwide with advanced or metastatic NSCLC and improved their survival outcomes (104).